PWE-135 Enterosorption as a supportive treatment during external radiotherapy in patients with uterine and cervical cancer

    loading  Checking for direct PDF access through Ovid



The most common adverse reactions of external pelvic radiotherapy include: frequent stools, frequent urination, dysuria, tenesmus, abdominal pain and blood count changes. To reduce them, patients should mind their diet, take enough fluids and use medications. One of the possibilities is Enterosgel, a selective enterosorbent.


We administered Enterosgel as a part of a clinical study “The role of Enterosgel in prevention of gastrointestinal adverse reactions of percutaneous radiation”. 90 patients with uterine or cervical cancer, treated by external pelvic radiotherapy, were divided into 2 groups: the first group included 46 patients who were given 45 g of Enterosgel per day, and the second group included 44 patients who didn’t take Enterosgel. We monitored the following parameters: ECOG, body weight, diarrhoea, nausea, leukocytes, thrombocytes and erythrocytes count and potassium and sodium levels.


There was no statistically significant difference between the two groups for blood count, electrolytes levels and ECOG. We found a statistically significant difference for body weight, number of diarrheal stools and number of days without nausea. Compared to patients who weren’t taking Enterosgel, patients in Enterosgel group lost 0.49 to 2.17 kg less (p-value=0.00234), had 0.47 to 6.29 less diarrheal stools (p-value=0.02325), and had 1.03 to 5.71 less days with nausea (p-value=0.005588).


- Our findings suggest that Enterosgel could be used as an effective supportive treatment to prevent or reduce diarrhoea , nausea and weight loss associated with pelvic radiotherapy


- This study provides further evidence that Enterosgel is safe and well-tolerated


- Further research will be required to confirm these preliminary findings

Disclosure of Interest

None Declared

Related Topics

    loading  Loading Related Articles